The introduction of CAR-T therapy has revolutionized the myeloma treatment landscape, offering a promising therapeutic approach for patients with relapsed/refractory (R/R) disease. There are currently two approved CAR-T cells in multiple myeloma: idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), with ongoing studies exploring the possibility of bringing these agents into earlier lines of treatment.
In this podcast, Maria-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, University College London Hospitals, London, UK, and Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, discuss the significance of CAR-T therapy in myeloma, how to select patients for CAR-T therapy, the evolving role of autologous stem cell transplantation (autoSCT), and more.
Managing anemia in MF, key emerging trials in the UK, and approaching young patients with MPNs
Highlights from EBMT 2024: treating & managing GvHD & understanding the role of the gut microbiome
The importance of cardio-oncology: awareness around the ESC 2022 guidelines & the value of building MDTs
Exploring the possibility of early interception in smoldering myeloma: novel agents, challenges & advances in risk stratification
CHIP & CCUS: knowledge gaps, ongoing trials & recommendations for approaching patients with myeloid precursors
Monoclonal B-cell lymphocytosis: classification, biology and exploring the possibility of early interception
Diagnosing amyloidosis, currently available therapies & the importance of cardio-oncology
Addressing the importance of lymphodepletion, factors contributing to ICAHT & the cost effectiveness of CAR-T therapy
Updates with the use of CAR-T therapy in ALL: ongoing challenges, strategies to overcome resistance & future outlooks
Targeted therapy in AML: the growing role of menin inhibitors & clinical trials exploring these agents
Updates in lower- and higher-risk MDS: challenges, novel agents & key clinical trials at ASH 2023
Key updates in thalassemia at ASH 2023: gene therapies, ongoing trials & the value of precision medicine
Updates, challenges and novel agents being explored in BPDCN
Unanswered questions regarding the sequencing of BCMA therapies, the prognostic value of CTCs & the growing role of quadruplets
Key updates in sickle cell disease at ASH 2023: disease biology, ongoing trials & the growing role of gene therapy
ASH 2023 highlights: updates in the diagnosis and treatment of amyloidosis
MPN highlights at ASH 2023: novel agents & ongoing clinical trials in ET, PV and MF
iwNHL 2023 Session V: Expanding the CAR platform in NHL
iwCLL 2023: The role of continuous BTKis, approaching Richter’s transformation & addressing the underrepresentation of elderly patients in trials
Create your
podcast in
minutes
It is Free
The Relaxback UK Show
Good Nurse Bad Nurse
On Call With Dr. Anselm Anyoha
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive